Anti-Allergy Medicine Market Report 2026

The anti-allergy medicine market size has grown strongly in recent years. It will grow from $42.25 billion in 2025 to $45.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to seasonal allergies, urban pollution, otc drug access, hospital allergy treatment, antihistamine availability.

The anti-allergy medicine market size is expected to see strong growth in the next few years. It will grow to $63.27 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to climate-related allergy increase, digital pharmacy growth, biologic allergy treatments, pediatric allergy awareness, healthcare access expansion. Major trends in the forecast period include rising prevalence of allergic conditions, growth of otc allergy medications, increased use of second-generation antihistamines, expansion of online pharmacy sales, focus on pediatric and geriatric formulations.

The rising prevalence of allergies is expected to drive the growth of the anti-allergy medicine market in the coming years. Allergies are hypersensitive immune responses to substances such as pollen, dust mites, food, or pet dander, causing symptoms ranging from mild irritation to severe, potentially life-threatening reactions. These include hay fever, asthma, eczema, food allergies, and allergic rhinitis. The increase in allergy cases is largely attributed to environmental pollution, which weakens the immune system and heightens sensitivity to common allergens. Anti-allergy medicines help manage these conditions by providing targeted relief, reducing immune overreactions by blocking histamines and other triggers, and improving daily comfort and quality of life. For example, in May 2025, the UK Parliament reported that 3,886,879 people over the age of six were diagnosed with asthma in 2023-24, representing 6.5% of England’s population. Therefore, the growing prevalence of allergies is fueling the growth of the anti-allergy medicine market.

Key companies in the anti-allergy medicine market are focusing on innovative therapies, such as monoclonal antibody treatments, to provide targeted relief, improve efficacy, reduce side effects, and address chronic or severe allergic conditions. Monoclonal antibody therapies are lab-engineered proteins that mimic the immune system’s ability to fight harmful allergens by specifically targeting and blocking immune pathways involved in allergic reactions, offering precise and long-lasting benefits. For instance, in December 2024, Galderma SA, a Switzerland-based pharmaceutical company, received FDA approval for Nemluvio (nemolizumab-ilto) for adults and pediatric patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors. Nemluvio is an interleukin-31 receptor antagonist that blocks IL-31 signaling, a key driver of inflammation and itch in atopic dermatitis, thereby reducing symptoms and improving skin condition.

In January 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for $850 million. Through this acquisition, Johnson & Johnson aims to strengthen its immunology portfolio by integrating Proteologix’s bispecific antibody programs to develop innovative treatments for immune-mediated conditions such as atopic dermatitis and asthma. Proteologix Inc., based in the US, focuses on anti-allergy medicines through novel bispecific antibody therapies targeting conditions such as asthma and atopic dermatitis.

Major companies operating in the anti-allergy medicine market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd., ALK-Abelló A/S, Torii Pharmaceutical Co. Ltd., Biomay Aktiengesellschaft, Kaléo Inc., Immunomic Therapeutics Inc., Circassia Group plc, Sun Pharmaceutical Industries Ltd., Anergis S.A., Aravax Pty Ltd., DBV Technologies S.A., Desentum Oy.

North America was the largest region in the anti-allergy medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-allergy medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-allergy medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the anti-allergy medicine market by increasing costs for active pharmaceutical ingredients, nasal spray components, and biologic allergy treatments. Antihistamines, corticosteroids, and injectable immunotherapy segments are most affected, especially in Asia-Pacific and North America due to international sourcing of raw materials. However, tariffs are accelerating domestic manufacturing and generic drug production, supporting cost control and supply chain resilience.

The anti-allergy medicine market research report is one of a series of new reports that provides anti-allergy medicine market statistics, including anti-allergy medicine industry global market size, regional shares, competitors with a anti-allergy medicine market share, detailed anti-allergy medicine market segments, market trends and opportunities, and any further data you may need to thrive in the anti-allergy medicine industry. This anti-allergy medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-allergy medicine refers to a broad group of pharmaceutical products designed to prevent or relieve symptoms caused by allergic reactions by modulating the immune system’s response to allergens such as pollen, dust, pet dander, insect stings, or certain foods and medications. These medicines help reduce symptoms like sneezing, itching, runny nose, hives, and watery eyes, alleviating discomfort caused by allergens.

The main drug classes of anti-allergy medicine include antihistamines, corticosteroids, decongestants, leukotriene inhibitors, mast cell stabilizers, and others. Antihistamines relieve allergy symptoms by blocking the effects of histamine, a chemical released during allergic reactions. They are used to treat various allergies, including seasonal, perennial, food, skin, and insect sting allergies, and are available in formulations such as tablets, capsules, syrups, nasal sprays, eye drops, and injectables. Anti-allergy medicines are distributed through channels like online pharmacies, hospitals, offline pharmacies, and clinics, serving end-users including children, adults, the geriatric population, and pregnant women.

The anti-allergy medicine market consists of sales of combination therapies, inhalers, nebulizers, auto-injectors, prefilled syringes, and transdermal patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.